Cargando…
Impact of enzalutamide on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives
Prostate cancer claims the lives of more than 25,000 men in the United States yearly, most from metastatic disease. In the past decade, several new medications have been approved for the treatment of metastatic prostate cancer including the antiandrogen enzalutamide. In addition, there has been moun...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5136356/ https://www.ncbi.nlm.nih.gov/pubmed/27942507 http://dx.doi.org/10.2147/RRU.S104789 |